IDEAYA Biosciences Future Growth
Future criteria checks 2/6
IDEAYA Biosciences is forecast to grow earnings and revenue by 41.9% and 56% per annum respectively. EPS is expected to grow by 43.6% per annum. Return on equity is forecast to be -3.3% in 3 years.
Key information
41.9%
Earnings growth rate
43.6%
EPS growth rate
Biotechs earnings growth | 32.0% |
Revenue growth rate | 56.0% |
Future return on equity | -3.3% |
Analyst coverage | Good |
Last updated | 24 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 87 | -170 | -211 | -207 | 9 |
12/31/2025 | 94 | -143 | -196 | -193 | 11 |
12/31/2024 | 12 | -176 | -124 | -122 | 11 |
3/31/2024 | 16 | -129 | -135 | -131 | N/A |
12/31/2023 | 23 | -113 | -118 | -115 | N/A |
9/30/2023 | 23 | -103 | -116 | -115 | N/A |
6/30/2023 | 45 | -74 | -111 | -109 | N/A |
3/31/2023 | 47 | -68 | -98 | -95 | N/A |
12/31/2022 | 51 | -59 | -91 | -87 | N/A |
9/30/2022 | 50 | -53 | -85 | -80 | N/A |
6/30/2022 | 29 | -66 | -72 | -69 | N/A |
3/31/2022 | 32 | -55 | -64 | -62 | N/A |
12/31/2021 | 28 | -50 | -58 | -56 | N/A |
9/30/2021 | 36 | -37 | -53 | -51 | N/A |
6/30/2021 | 36 | -30 | 50 | 52 | N/A |
3/31/2021 | 27 | -31 | 50 | 51 | N/A |
12/31/2020 | 20 | -34 | 55 | 55 | N/A |
9/30/2020 | 9 | -40 | 58 | 58 | N/A |
6/30/2020 | N/A | -46 | -43 | -42 | N/A |
3/31/2020 | N/A | -44 | -40 | -39 | N/A |
12/31/2019 | N/A | -42 | -41 | -39 | N/A |
9/30/2019 | N/A | -40 | -40 | -38 | N/A |
6/30/2019 | N/A | -42 | -39 | -36 | N/A |
3/31/2019 | N/A | -38 | -34 | -32 | N/A |
12/31/2018 | N/A | -34 | -29 | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 30J is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 30J is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 30J is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 30J's revenue (56% per year) is forecast to grow faster than the German market (5.3% per year).
High Growth Revenue: 30J's revenue (56% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 30J is forecast to be unprofitable in 3 years.